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Abstract
Autism spectrum disorder (ASD) is a heterogeneous
neurodevelopmental disorder that has been confirmed
to be related to some genetics risk factors which can
lead to different clinical phenotypes. At present, ASD is
mainly diagnosed based on some behavior and
cognitive scales, which can not reveal the mechanism
of disease occurrence, development and prognosis. In
recent years, some studies have applied omics
techniques into ASD research, but these studies are
only based on single omics data source such as
genomics, proteomics or transcriptomic without
investigating ASD subtypes from integration of multiomics data. In this study, we proposed an ASD
subtyping framework that integrates clinical and multiomics data to identify and analyze ASD subtypes at the
molecular level. Due to the heterogeneity of different
data modalities, a fusion clustering strategy was used
to produce more accurate and interpretable clusters.
Based on ASD subtyping results, we also proposed a
classification framework to predict the subtype of new
ASD patients. Deep learning method was used to
extract features from each data modality, then all
extracted features were integrated by the multiple
kernel learning method to improve the classification
accuracy.

1. Introduction
Autism Spectrum Disorder (ASD) is a
neurodevelopmental
disorder
characterized
by
impaired communication and social interaction as well
as restricted and repetitive interests and behaviors [1].
ASD is now diagnosed mainly based on Diagnostic
and Statistical Manual of Mental Disorders, Fifth
Edition (DSM-5) criteria and various behavior scales
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such as Autism Diagnostic Observation Schedule
(ADOS) , Autism Diagnostic Interview, Revised (ADIR) [2]. However, this behavior-based diagnosis method
does not define any subtypes that can reflect
phenotypic heterogeneity of ASD and facilitate better
understanding of etiology of the condition. In recent
years, some ASD subtyping studies based on clinical
manifestation or behavioral symptoms have emerged
[3, 4], but the symptoms on ASD patients change
significantly with the increase of age, resulting in
subjective and unreliable subtyping results that are also
difficult to elucidate the etiology of each ASD
phenotype. With the wide application of artificial
intelligence on medical image analysis, a large body of
research has emerged using multiple Magnetic
Resonance Imaging (MRI) techniques finding impaired
functional and structural connectivity between brain
regions. And these abnormalities in connectivity
sometimes can be used as biomarkers for the diagnosis
of ASD in clinic.
However, the biomarkers obtained in these imaging
studies are not always consistent, making it impossible
to achieve clinical reliability by relying only on
medical imaging [5, 6]. The reason for this
inconsistence is that each ASD subtype has its distinct
characterizations in brain, while most imaging studies
do not take into account the heterogeneity between
different ASD subtypes. So if considering patient
subtypes in imaging analysis, it can improve the
reliability of ASD clinical diagnosis and treatment. At
present, there are studies explaining the imaging
heterogeneity of ASD patients from molecular
perspective. For example, Qureshi et al found that
16p11.2 chromosome deletion leads to an increase in
brain volume, while its duplication leads to a decrease
in brain volume [7]. Some studies also revealed how
ASD risk genes (such as CNTNAP2, MET) affect
brain structure and function networks [8, 9]. These
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studies have emphasized the important role of
inheritability in ASD diseases. And combining genes
and imaging can facilitate the discovery of more
accurate ASD imaging biomarkers.
Behavioral assessment and imaging diagnosis both
have certain limitations and neither one can reveal the
etiology of ASD. With the continuous advancement in
basic scientific research especially in the fields of
genetics and neuroscience, researchers have
determined that ASD is a kind of diffuse
developmental disorder of the central nervous system
caused by a variety of environmental factors under the
influence of certain genetic factors. In 2009, the NIMH
conducted a research project called Research Domain
Criteria (RDoC) [10], which aims to transcend the
limits of traditional classification method, combining
genetics, neuroscience, behavioral science and other
methods to clarify the neural basis and biomarkers of
mental illness. This project implies that we can find
more clinically relevant ASD subtypes and biomarkers
by integrating multiple data sources such as genetic,
neuroimaging, behavioral assessment, and patient
clinical history to achieve personalized healthcare and
improved prognosis for patients with ASD.
In the past few decades, scientists have been
actively exploring the genetic basis of ASD using
methods such as cytogenetic research, linkage analysis,
and association analysis of candidate genes [11]. The
findings show that ASD is a complex disease with high
level of genetic heterogeneity. In recent years, great
progress has been made in the identification of ASD
genetic pathogenicity loci. At present, there are
hundreds of pathogenic genes associated with ASD,
most of which are rare and have various types of
mutations [12]. In addition to the mutations inherited
from parents, many ASD de novo mutations have been
discovered by using the whole-exome sequencing
technique, and the number of identified mutations is up
to more than 1000 [13]. Iossifov et al. used wholeexome sequencing find that in a family with only one
ASD patient, new gene mutations such as copy number
variant (CNV) accounted for approximately 30% of
ASD cases [14]. Common genetic variants such as
single nucleotide polymorphism (SNP) also influence
the onset of ASD. Although many ASD-related
pathogenic genes have been found, the high level of
inheritance heterogeneity is far from explaining the
pathogenesis of ASD. Transcriptomics studies use
cDNA microarrays and high-throughput RNA
sequencing technology to obtain gene expression data,
combining with gene co-expression network analysis
to discover the molecular mechanisms related to ASD
[15, 16]. Proteomics studies have found that the
clinical manifestations of ASD may be related to
changes in proteins, such as mutations leading to

changes in protein and amino acid sequences, and
mutations in gene regulatory regions leading to
changes in protein expression or abnormal
modification of proteins [17, 18]. In recent years, the
acquisition
of
specific
biomarkers
through
metabolomics research is effective for early ASD
screening and diagnosis. Currently, some analytical
techniques such as gas chromatography-mass
spectrometry (Gc-Ms), capillary electrophoresis-timeof-flight mass spectrometry (CE-TOF), liquid
chromatography-mass spectrometry (Lc-Ms), nuclear
magnetic resonance (NMR) have been widely used in
ASD urine or blood metabolite analysis. By
comparison with the healthy controls, the significant
differences in metabolites are mainly related to
intestinal microbial metabolism, energy metabolism,
oxidative stress [19-21]. At present, it has been found
that ruminococcus, clostridium and desulfovibrio in the
gastrointestinal tract of ASD are significantly different
from healthy controls [22, 23]. The damage to normal
nerve development caused by gastrointestinal
microflora and its metabolites is one of the ASD
etiology research directions. Through bacterial tagencoded FLX amplicon pyrosequencing (bTEFAP)
technique, DNA is directly extracted from feces of
ASD patients for sequencing to determine specific
bacterial composition, and then all microorganisms in
the intestine can be identified [24].
In summary, most of the above studies are based on
single omics data source and did not systematically
analyze and explore ASD subtypes. The
characterization of each omics technique on ASD
subtype level has not yet been studied as well as the
interaction between different omics data and their
distinct regulatory role on signaling pathways. To
solve this problem, we proposed an ASD subtyping
framework by fusing multi-omics and clinical
assessment data using the unsupervised clustering
method. Then for subtype prediction of a new
unknown patient, we proposed a classification
framework based on the multi-omics data and
clustering results. Due to the complexity and high
dimensionality of omics data, deep learning method
was used to automatically extract discriminative
features from all omics data. Then we used the
multiple kernel learning (MKL) method to explore
complementary information among these features and
discover different contribution of relevant omics
features.

2. ASD subtyping based on multi-omics
data
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Studies have shown that ASD is highly heritable,
and that each ASD-related gene mutation or CNV will
result in a different clinical phenotype. However, due
to the etiology complexity of ASD, it is generally
possible to find pathogenic genes distributed on
different chromosomes in patients. At the same time,
due to the difference in gene expression and the
interaction of multiple genes in a common path, ASD
appears in clinical phenotype with high level of
heterogeneity. Therefore, we propose an ASD
subtyping framework by integrating clinical and multiomics data to discriminate among distinct ASD
subtypes.
Cluster analysis is a major analytical method for
disease subtypes based on high-dimensional omics data.
It can classify functionally related genes (or other
omics data) according to the consistent trend or
proximity of expression levels. It has already been
widely used in cancer subtyping [25]. Cluster analysis
generally needs to establish an accurate measure of the
"distance" between samples. The measurement
methods include Euclidean distance, Chebyshev
distance, Manhattan distance, Minkowski distance,
angle cosine, Pearson correlation coefficient and so on.
Since the clustering results are susceptible to a large
amount of noise in the omics data, and the omics data
is usually very high in dimension, it is necessary to use
data dimensionality reduction methods before cluster
analysis such as Principal Component Analysis (PCA) ,
Partial Least Square (PLS), etc. removing data
containing useless information. In the field of
bioinformatics analysis, common clustering algorithms
include Hierarchical Clustering, K-means, Fuzzy Cmeans, and Self- Organizing Maps and so on.
The above cluster analysis methods are mainly
based on the statistical theory that the knowledge in the
biological field is rarely used, so that the clustering
result does not produce the reasonable biological
interpretation that people need to understand the
disease. In addition, it is more important to combine
and fuse different kind of omics data effectively for
clustering. The easiest way is to concatenate feature
matrix of each omics data source directly, but this
approach will result in a further lower signal-to-noise
ratio. Another way is to cluster individually for each
omics data source and then merge the clustering results.
However, the potential inconsistencies between each
clustering results may cause merge errors. Currently,
there are two methods for the fusion clustering of
different genomics data in the field of tumor research,
including the iCluster [26] method based on the joint
latent variable model and the SNF [27] method based
on the sample similarity network. Studies have shown
that SNF has better performance in tumor subtyping
than iCluster [27].

In ASD subtyping, we can also use the above two
methods to perform fusion cluster analysis on various
omics data (such as gene expression, protein
expression, etc.) and compare the different
performance between the two methods. Since cluster
analysis is an unsupervised learning method, its
clustering results can not be tested by ground truth.
The biostatistical method can be used to perform
statistical tests on clustering results, including survival
analysis, contour coefficients and clustering statistical
significance test. The multi-omics based ASD
subtyping framework is shown in Figure 1.

Figure 1. Framework of multi-omics based
ASD subtyping

3. Subtype prediction of new ASD patients
After ASD subtyping, it is also necessary to
construct a classification model that can distinguish
between different ASD subtypes. A wide range of
supervised learning methods are available to build a
classifier that is used to predict the subtype of a new
ASD patient. Since the multi-omics and clinical
evaluation data are integrated when producing ASD
subtype clusters, it is also beneficial to improve the
model performance that integrating different data
modalities to obtain complementary information when
building an ASD subtype prediction model. Deep
learning method is suitable for extracting more
discriminative features from high-dimensional and
complex data. The extracted features from each data
modality then can be integrated to further improve the
model performance. The ASD subtype prediction
framework is shown in Figure 2.
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Convolutional Neural Network (CNN) is a
feedforward neural network derived from biological
nerves. It is a multi-layer perceptron model designed to
recognize two-dimensional images and has certain
invariance to image transformation. CNN is composed
of three components including the convolutional layer,
the pooling layer, and the fully connected layer, and it
has some advantages such as network weight sharing
and direct input of the original image. Although CNN
is mainly used in the field of computer vision, its
powerful feature analysis capabilities can also be used
for the processing of biological omics data [28]. There
are many CNN models such as LeNet-5, Inception v3
etc. that can be used to extract features from multiomics and clinical data.

Integrating multiple heterogeneous omics data
sources such as genomic, proteomic, metabolomic, etc.
can lead to better classification than simply using one
data source alone. Support Vector Machine (SVM) is a
supervised learning method and commonly used in
classification problems. The optimal performance of
SVMs is highly dependent on the kernel function used.
Cross validation is the standard approach to select the
best kernel function among a set of candidates such as
linear kernel, polynomial kernel and gaussian kernel.
However, SVM is not suitable for analyzing multiple
data sources using a single kernel function. We can use
Multiple Kernel Learning (MKL) method to combine
kernels calculated on different input data modality to
obtain better predictive performance [29,30].

Figure 2. ASD subtype prediction framework

4. Discussion
The molecular subtyping has been successfully
applied to cancer research and there are many
publicly available repositories such as the Cancer
Genome Atlas (TCGA), Multi-Omics Profiling
Expression
Database
(MOPED),
Oncomine,
ArrayExpress, COSMIC etc. In the field of ASD
research, the National Database for Autism Research
(NDAR) allows a researcher to associate a single
research participant’s anonymized genetic, imaging,
clinical assessment and other information to analyze
the ASD and its subtypes [31]. This paper proposed

an ASD subtyping framework based on molecular
multi-omics data which can be obtained from the
public databases or from the private medical
institutions. Unsupervised clustering methods were
used to fuse the clinical and multi-omics data to
group them into different clusters. Once the ASD
subtypes are generated, they can be characterized by
combining the clusters with existing pathway or
interaction network knowledge to increase the
interpretability of the generated ASD subtypes.
Another framework this paper proposed is the
classification model to accurately predict the
subtypes of new ASD patients. In this framework,
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CNN network was used to extract discriminative
features from various data modalities. In order to
differentiate the contributions or weights to the
classification of each modality, we intended to
leverage the MKL technique to learn the optimal
combination coefficients of different kernel functions,
which is expected to improve the subtype prediction
accuracy. Of note, there are challenges and
impediments for ASD subtyping due to data
heterogeneity, diversity of standards and analysis
tools, variability of experimental procedures.
However, compared to ever-changing psychiatric
nosological definitions such as DSM-5, ASD
subtyping from molecular perspective holds the
promise of better personalized healthcare and
precision medicine for ASD patients with specific
manifestations.
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